Cadila Healthcare is aiming high: it is gunning for revenues of R10,000 crore by FY 2016. India's fourth largest pharmaceutical company, and the manufacturer of India's first new drug Lipaglyn, aims to accelerate growth by expanding product ... Financial Express, 1 day ago
Near-term headwinds for pharma companies - Smart Investor, 2 weeks ago
Pharma shares extend fall; CNX Pharma index down 3% - Business Standard, 2 weeks ago
Cadila Healthcare has informed that a meeting of the Board of Directors of the Company will be held on May 15, 2015, to approve the audited stand-alone and consolidated financial results for the quarter / year ended on March 31, 2015 and to recommend the ...Money Control, 1 week ago CADILA HEALTHCARE : SEEKS CREDIT LIMIT OF Rs10,000 CRORE 4 Traders, 3 weeks ago Outcome of board meeting of Cadila Healthcare Capital Market, 3 weeks ago Cadila Healthcare plans to raise Up to Rs. 3,500 Cr Via NCD Issue India Infoline, 3 weeks ago
In a rare interview, Pankaj Patel, chairman and managing director of India's fourth-largest pharma company, Cadila Healthcare, tells Neha Bothra that the company is looking to expand its biosimilars portfolio through its own R&D efforts and expects ...Financial Express, 1 week ago CADILA HEALTHCARE: BIOSIMILARS SHOULD CONTRIBUTE 10% TO OUR REVENUE IN 5 YEARS Pharmacy Choice, 6 days ago
Cadila Healthcare gains on announcing a collaborative program with the National Institute of Alle...
Cadila Healthcare is currently trading at Rs. 1755.80, up by 7.35 points or 0.42 % from its previous closing of Rs. 1748.45 on the BSE. The scrip opened at Rs. 1770.00 and has touched a high and low of Rs. 1770.00 and Rs. 1742.20 respectively. So ...Arihant Capital, 1 week ago Cadila Healthcare gains on inking non-exclusive licensing pact with Gilead Sciences Arihant Capital, 1 month ago
Cadila Healthcare revealed that its US subsidiary Etna Biotech will collaborate with the US national Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to develop a vaccine against visceral leishmaniasis, The Economic ...FirstWord Pharma, 1 week ago Zydus ties up with US-based R&D to develop vaccine Hindu Business Line, 1 week ago Zydus ties up with US-based RD centre to develop vaccine Moneycontrol.com, 1 week ago
More from: , Daily Excelsior.com...and 2 other sources
NEW DELHI: The Indian equity market has underperformed other emerging markets in the last few months due to rising concerns over subdued growth in the earnings of domestic corporates, possibility of a delayed revival in economic activity, unseasonal ...Economic Times, 10 hours ago 10 stocks in focus; Sensex ignores Moody's Economic Times, 3 weeks ago Top 12 stocks which can deliver up to 50% return Economic Times, 1 month ago
AHMEDABAD: Pharma companies in Gujarat are increasingly focusing on . Several companies are either expanding their existing line of personal care products or setting up new divisions to cater to the growing wellness market in the country. For ...Times of India, 1 day ago Gujarat's pharma firms bank on wellness Times of India, 1 day ago
If the proposed bill on Indian Institutes of Management (IIM) is used to bring about centralization of key processes, it would be bad news for these institutions and their autonomy, believes Ashish Nanda , director of IIM Ahmedabad (IIMA) India's ...Livemint.com, 1 day ago
/PRNewswire/ -- A new report by visiongain forecasts the overall world market for antithrombotic drugs will reach $22.4bn in 2019. That revenue forecast and others appear in , published in March 2015 . The purpose of that investigation is to ...Tamar Securities, 4 days ago
Today's planetary position: Moon will be transiting in Virgo. Jupiter in Cancer. Lord Rahu in Virgo, Lord Saturn in Scorpio. Mars and Sun in Aries, Venus and Mercury in Taurus, Ketu in Pisces. Pluto in Sagittarius. Neptune in Aquarius and Uranus in ...Moneycontrol.com, 5 days ago Stock market prediction for March 9-13: Satish Gupta Moneycontrol.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!